tcr

α-Galactosylceramide (KRN7000) is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

Anti-Mouse TCR gamma/delta Antibody is an IgG class inhibitor derived from the host Armenian Hamster, targeting the mouse TCR gamma/delta receptor.

Anti-Mouse TCR V gamma 2 Antibody is an inhibitory IgG antibody derived from Armenian Hamster, targeting mouse TCR V gamma 2.

Anti-Mouse Vβ8 TCR Antibody (F23.1) is an IgG2a, κ antibody inhibitor derived from mice, targeting mouse Vβ8 TCR.

Anti-Mouse 2C TCR Antibody (1B2) is an IgG1 antibody inhibitor derived from mice, specifically targeting the mouse 2C TCR.

Anti-Rat TCR alpha/beta Antibody (R73) is an IgG1, κ antibody inhibitor derived from mice, targeting rat TCR α/beta.

Anti-Rat TCR gamma/delta Antibody (V65) is an IgG1, κ antibody inhibitor derived from mice, targeting rat TCR γ/δ.

Anti-Mouse Vβ4 TCR Antibody (KT4) is an IgG2b inhibitor antibody of rat origin that targets the mouse Vβ4 TCR.

Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an IgG antibody inhibitor derived from the U.S. hamster, targeting mouse TCR Vγ1.1/Cr4.

Anti-TCR Antibody (NKTT320) represents a highly specialized humanized agonistic monoclonal antibody specifically engineered to target the invariant T-cell receptor of iNKT cells with exceptional binding affinity and selectivity, effectively facilitating the measurable activation and expansion of this unique lymphocyte subset across various preclinical experimental models to evaluate the induction of immunomodulatory cytokines during strictly monitored laboratory observation periods.

Anti-Mouse TCRβ Antibody (HB218) is an IgG antibody inhibitor derived from American hamster, specifically targeting mouse TCRβ.

TCRS-417 (T417) inhibits PBX1-DNA interaction in mammalian cells or cell clusters, used in autoimmune and neurodegenerative disease research.

Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.

IHVR-17028 is a potent broad-spectrum ERα-glucosidase I (α-glucosidase I) inhibitor with IC50 of 0.24 μM and antiviral activity. IHVR-17028 inhibited BVDV, TCRV and DENV, and EC50 values were 0.4 μM, 0.26 μM and 0.3 μM, respectively. IHVR-17028 can be used to study infectious diseases.

T.cruzi Inhibitor hydrochloride is a Trypanosoma cruzi inhibitor.

DST crosslinker(disuccinimide tartarate) is an isotype bifunctional, cleavable crosslinker (cleavable by an oxidizer) for applications that require crosslinking cleavability and that do not interfere with protein disulfide bonds with reducing agents.

(S)-crizotinib (ent-crizotinib) （IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

PI3K/Akt/CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease.

Urocortin, rat TFA is a neuropeptide and a potent endogenous CRFR agonist (Kis: 0.97 nM, 1.5 nM, and 13 nM for mouse CRF2β, rat CRF2α, and human CRF1).

KRM-III is an orally active T cell antigen receptor (TCR) inhibitor with anti-inflammatory activity that potently inhibits TCR and myristate acetate/fosfomycin/ionomycin-induced NFAT nuclear factor activation and T cell proliferation, with an IC50 of approximately 5 μM.

PF-07265028 is an HPK1 inhibitor with an IC50 of 17 nM. Pharmacokinetic studies in mice and monkeys indicate that PF-07265028 exhibits moderate clearance, terminal half-life, volume of distribution, and oral bioavailability. It targets, binds, and inhibits Hpk1 activity, blocking Hpk1-mediated signaling pathways to prevent immune suppression mediated by Hpk1, including the inhibition of T-cell receptor (TCR) signaling, effector T-cell suppression, aberrant cytokine expression, and the elimination of the immunosuppressive tumor microenvironment (TME). This action can activate a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells. Hpk1 is primarily expressed in hematopoietic cells and acts as a negative regulator of TCR signaling and T and B cell activation.

CD73-IN-19 (Compound 4ab) is an inhibitor of CD73, demonstrating a 44% inhibition rate of CD73 enzyme activity at 100 μM. It entirely counters T cell proliferation blockade triggered by TCR activation (induced by CD73 activity) at 10 μM and 100 μM and inhibits hA2A receptor activity in HEK-293 cells with a Ki of 3.31 μM. CD73-IN-19 holds potential for research in the field of immune diseases.

6-Thio-GTP (tetrasodium) is an inhibitor of Vav1-Rac. It can suppress TCR-induced T cell proliferation and CD28-mediated T cell survival. In a murine model of allogeneic heart transplantation, 6-Thio-GTP (tetrasodium) demonstrates immunosuppressive effects, which can prolong the survival time of heart transplants.

PROTACHPK1 Degrader-1 (Compound B1) is a potent HPK1 degrader with a DC50 value of 1.8 nM. It effectively inhibits the phosphorylation of the SLP76 protein, with an IC50 of 496.1 nM. As a genuine HPK1-PROTAC degrader, PROTACHPK1 Degrader-1 offers a valuable tool for further investigation into HPK1 in TCR signaling pathways.